Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age45-84
SponsorUniversal Diagnostics

About this trial

This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.

Eligibility criteria

Qualifiers

Arm A: Diagnosed with CRC

Arm B: Undergoing screening with colonoscopy for CRC

Disqualifiers

Arm A: Undergoing treatment for CRC,

Arm B: Past history of CRC

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

6,500 Participants
are grouped into 2 trial groups

Sponsors and collaborators